Wegovy Adolescent (12 to 17) Monitoring: Labs, Growth, and Mental Health Checks

Why Adolescent Monitoring Differs From Adult Protocols

Teenagers on semaglutide 2.4 mg are not small adults. Active linear growth, pubertal development, and the higher prevalence of eating disorders in this age group demand a monitoring framework purpose-built for patients aged 12 to 17. The FDA expanded Wegovy's indication to this population in December 2022 based on STEP TEENS data, but the prescribing label leaves much of the monitoring schedule to clinical judgment 1.

Growth Is the Core Differentiator

Adults have finished growing. Adolescents have not. Caloric restriction layered on top of a GLP-1 receptor agonist's appetite-suppressing effect could, in theory, blunt height velocity or delay puberty. STEP TEENS did not signal growth impairment over 68 weeks, but the trial was not powered to detect subtle changes in final adult height 2. Height should be measured with a stadiometer (not estimated) every 3 months and plotted on CDC growth charts.

Puberty-Specific Considerations

Tanner staging at baseline and annually gives clinicians a reference point. If pubertal progression stalls or height velocity drops below the 10th percentile for age and sex, a pediatric endocrinology referral is appropriate. The Endocrine Society's 2023 pediatric obesity guideline recommends ongoing growth surveillance "for the duration of pharmacotherapy in any child or adolescent who has not reached final adult height" 3.

Baseline Laboratory Workup

Before writing the first Wegovy prescription for a teenager, a structured lab panel establishes metabolic risk and rules out contraindications. This baseline also serves as the comparison point for all future monitoring.

Metabolic and Endocrine Labs

Draw fasting glucose, HbA1c, a comprehensive lipid panel (LDL, HDL, triglycerides, total cholesterol), hepatic aminotransferases (ALT, AST), and TSH. Semaglutide carries a boxed warning regarding medullary thyroid carcinoma in rodents, and while human risk remains unproven, a baseline TSH with reflex calcitonin is reasonable in patients with a family history of MEN2 or medullary thyroid cancer 4. Fasting insulin and HOMA-IR are optional but useful for tracking insulin sensitivity improvements over time.

Nutritional and Bone Health Markers

Adolescents in active growth need calcium, iron, and vitamin D. Check 25-hydroxyvitamin D, serum ferritin, and a CBC at baseline. In STEP TEENS, caloric intake dropped alongside appetite, and participants on semaglutide consumed fewer calories without specific dietary counseling 2. That reduction can unmask marginal deficiencies. Bone density testing (DXA) is not routine but should be considered if vitamin D stays low or if the patient has a fracture history.

Renal Function

Serum creatinine and eGFR at baseline screen for pre-existing renal issues. GLP-1 receptor agonists have shown renal protective effects in adults with type 2 diabetes in the FLOW trial (N=3,533), where semaglutide reduced the risk of kidney disease progression by 24% compared to placebo 5. Adolescent-specific renal outcome data do not yet exist, but dehydration from GI side effects (vomiting, diarrhea) can temporarily raise creatinine, making a clean baseline valuable.

Ongoing Laboratory Monitoring Schedule

Repeat labs should follow a rhythm tied to clinical milestones rather than arbitrary calendar dates. The dose escalation phase (weeks 1 to 16) is the highest-risk window for GI adverse events and the period when metabolic parameters begin to shift.

During Dose Escalation (Weeks 1 to 16)

Check a basic metabolic panel at week 8 if the patient reports persistent vomiting or diarrhea. Electrolyte disturbances (hypokalemia, metabolic alkalosis) can develop in adolescents who vomit frequently. A lipase level is warranted only if the patient reports severe epigastric pain radiating to the back; routine lipase screening is not recommended by the American Academy of Pediatrics 6.

Maintenance Phase (Post Week 16)

Once the patient reaches the 2.4 mg maintenance dose, repeat the full metabolic panel (fasting glucose, HbA1c, lipids, hepatic panel) at month 6 and then every 6 months. TSH annually. Nutritional markers (vitamin D, ferritin, CBC) every 6 months or sooner if dietary intake is concerning. The Endocrine Society recommends that "metabolic comorbidity screening should continue at regular intervals regardless of weight trajectory" in adolescents receiving anti-obesity pharmacotherapy 3.

Mental Health Surveillance

This is the monitoring domain clinicians most often underestimate. Weight loss pharmacotherapy in teenagers intersects with body image, peer dynamics, and a developmental stage where mood disorders and eating pathology peak.

Screening for Suicidal Ideation

The FDA's Wegovy label includes a warning about suicidal behavior and ideation based on post-marketing reports across GLP-1 receptor agonists 4. Screen using the Columbia Suicide Severity Rating Scale (C-SSRS) or the PHQ-A at every visit. In STEP TEENS, psychiatric adverse events occurred in 4.4% of semaglutide-treated adolescents versus 3.5% on placebo, a non-significant difference 2. Small numbers. But the consequence of missing a signal is too high to rely on trial-level reassurance alone.

Eating Disorder Screening

Rapid weight loss in a teenager can trigger or unmask restrictive eating patterns. Ask directly about food restriction, purging behaviors, binge episodes, and body image distress. The EDE-QS (Eating Disorder Examination Questionnaire, Short Form) takes under 5 minutes and can be administered in the waiting room. If a patient scores above clinical threshold, pause dose escalation and involve a behavioral health specialist before continuing.

Mood and Social Functioning

Weight loss changes how teenagers move through their social world. Some patients experience improved self-esteem and social engagement. Others develop anxiety about weight regain or feel pressure to "perform" thinness. A brief check-in about school performance, peer relationships, and sleep quality at each visit can surface problems early. Document findings in structured notes so trends become visible across visits.

Gastrointestinal Side Effect Management

GI symptoms are the most common reason adolescents consider stopping Wegovy. In STEP TEENS, 42% of semaglutide-treated participants reported nausea, 22% reported vomiting, and 16% reported diarrhea 2. These rates were higher than in adult STEP trials, where nausea occurred in 44% of adults in STEP-1 (N=1,961) but was generally milder in severity 7.

Practical GI Monitoring

At each visit during dose escalation, ask about nausea frequency, vomiting episodes per week, and stool consistency. Use a simple 0 to 10 severity scale. If nausea exceeds 6/10 or vomiting occurs more than twice per week, hold the current dose for an additional 4 weeks before escalating. Assess hydration status clinically (mucous membranes, skin turgor, orthostatic vitals). Persistent vomiting warrants a basic metabolic panel to check electrolytes.

When to Slow or Pause Escalation

Dose escalation should not be treated as a fixed 16-week sprint. If a teenager cannot tolerate a given dose after 4 weeks, drop back to the previous dose for another 4 weeks and re-attempt. The prescribing information permits this flexibility. Slow escalation reduces dropout rates and may improve long-term adherence, though no randomized trial has directly tested this specific strategy in adolescents.

Nutritional Monitoring and Dietary Guidance

Semaglutide suppresses appetite through central GLP-1 receptor activation in the hypothalamus and brainstem 8. For a 14-year-old in active growth, reduced caloric intake without nutritional guidance risks protein, calcium, and iron deficiency.

Protein Adequacy

Adolescents need approximately 0.85 to 1.0 g of protein per kg of body weight daily for normal growth, per the Dietary Reference Intakes. Weight loss increases protein requirements because muscle preservation demands higher intake. Target 1.0 to 1.2 g/kg/day during active weight loss. Ask about protein sources at each visit. A food frequency questionnaire or 24-hour recall every 3 months provides actionable data.

Micronutrient Surveillance

Iron deficiency is common in adolescent females independent of Wegovy use. Reduced food intake magnifies the risk. Check ferritin every 6 months. Vitamin D (25-OH) should stay above 30 ng/mL; supplement if below 20 ng/mL. Calcium intake should meet the 1,300 mg/day recommendation for ages 9 to 18 per the National Institutes of Health 9. A registered dietitian consult at treatment initiation and every 6 months is the standard of care recommended by the AAP clinical practice guideline for pediatric obesity 6.

Physical Activity and Body Composition Tracking

BMI alone is a poor proxy for treatment success in adolescents because it does not distinguish fat mass from lean mass. A teenager who gains muscle while losing fat may show minimal BMI change yet have meaningful metabolic improvement.

What to Measure

Waist circumference, measured at the iliac crest, correlates with visceral adiposity better than BMI in pediatric populations 10. Track it every 3 months. Body composition via bioelectrical impedance analysis (BIA) is available in most clinical settings and provides fat mass and lean mass estimates. DXA is more accurate but harder to justify for routine monitoring given radiation exposure and cost.

Exercise Counseling as a Monitoring Variable

Document physical activity at each visit: type, frequency, and duration. The 2023 AAP guideline recommends 60 minutes of moderate-to-vigorous physical activity daily for adolescents with obesity 6. Resistance training at least 2 days per week helps preserve lean mass during GLP-1-mediated weight loss. Record adherence as a clinical data point, not a suggestion patients nod at and forget.

Cardiovascular and Metabolic Risk Tracking

Adolescent obesity often presents with early cardiometabolic risk factors that respond to semaglutide. Track these improvements as rigorously as you track side effects.

Blood Pressure and Heart Rate

In STEP TEENS, semaglutide reduced systolic blood pressure by a mean of 2.8 mmHg compared to placebo 2. GLP-1 receptor agonists also increase resting heart rate by 2 to 4 beats per minute in most trials. Measure both at every visit. A resting heart rate persistently above 100 bpm warrants further cardiac evaluation.

Lipids and Glycemic Markers

In adults, STEP-1 showed that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo, with parallel improvements in waist circumference, HbA1c, and C-reactive protein 7. STEP TEENS demonstrated similar directional metabolic benefits: fasting insulin decreased, triglycerides improved, and HDL cholesterol increased in the semaglutide group 2. Re-check the full lipid panel and HbA1c at 6 months and annually after that.

Gallbladder Surveillance

GLP-1 receptor agonists slow gallbladder motility. Rapid weight loss independently raises cholelithiasis risk. The combination makes adolescents on Wegovy a population worth watching. In adult semaglutide trials, cholelithiasis occurred in 1.6% of treated patients versus 0.7% on placebo 4.

Ask about right upper quadrant pain, postprandial discomfort, and nausea that worsens after fatty meals at each visit. Do not order routine abdominal ultrasound for screening. Reserve imaging for symptomatic patients. If gallstones are confirmed, a surgical consult is appropriate, but Wegovy does not necessarily need to be stopped unless the patient requires cholecystectomy.

Treatment Duration and Discontinuation Planning

No guideline specifies how long an adolescent should remain on semaglutide. The STEP TEENS extension data suggest weight regain occurs after discontinuation, consistent with adult data from STEP-4, where participants who switched from semaglutide to placebo at 20 weeks regained two-thirds of lost weight by week 68 11.

Discuss treatment duration at the outset. Set expectations that Wegovy may be a long-term medication, not a short-term intervention. If discontinuation is planned (insurance loss, patient preference, transition to adult care), taper gradually rather than stopping abruptly, and increase the frequency of dietary counseling and exercise monitoring during the transition period.

At the final pediatric visit before transition to adult care, provide a summary document listing baseline and current labs, growth trajectory, mental health screening history, and the current dose. The receiving adult clinician needs this context to continue safe prescribing.